Frontage Holdings Corp. stock analysis
Frontage Holdings Corp. (FGHQF) Stock Price & Analysis
FGHQF Stock Chart & Stats
- Day’s Range
- $0.18 - $0.18
- 52-Week Range
- $0.11 - $0.20
- Previous Close
- $0.18
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $387.94M
- Enterprise Value
- $2.76B
- Total Cash (Recent Filing)
- $36.82M
- Total Debt (Recent Filing)
- $140.87M
- Price to Earnings (P/E)
- 36.5
- Beta
- -0.24
- Next Earnings
- Mar 29, 2027 (Est.)
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Long-term Revenue Expansion
Revenue expanded strongly from 2020 to 2025, with a sharp rebound in 2025 after a slight 2024 decline. This demonstrates the company’s ability to grow its property-related business over time, although recent growth has been uneven.
Manageable Leverage
Moderate leverage and lower debt in 2025 provide a relatively resilient financial base. This should preserve more flexibility for property operations and capital allocation than a highly leveraged balance sheet, while reducing pressure from debt obligations.
Consistently Positive Operating Cash Flow
Consistently positive operating cash flow indicates that the company’s core activities have generated cash across the reviewed period. That recurring inflow supports financial flexibility and can help fund obligations and operations even when free cash flow varies.
Bears Say
Structural Margin Compression
The sustained decline in gross margin shows that revenue growth has not translated into comparable profitability. With margins well below earlier levels, the company may have less earnings cushion and reduced capacity to absorb operating or property-market pressures.
Very Low Return On Equity
ROE near 2% indicates that the company is generating limited profit from its equity base despite maintaining acceptable leverage. Persistently weak capital returns can constrain internally generated growth and signal that asset deployment is not yet highly productive.
Volatile Free Cash Flow
The sharp 2025 free-cash-flow decline, despite better reported earnings, indicates weak conversion of accounting profit into deployable cash. Continued volatility could limit funding for operations, investment, or shareholder returns and make financial planning less predictable.
Frontage Holdings Corp. News
FGHQF FAQ
What was Frontage Holdings Corp.’s price range in the past 12 months?
What is Frontage Holdings Corp.’s market cap?
When is Frontage Holdings Corp.’s upcoming earnings report date?
How were Frontage Holdings Corp.’s earnings last quarter?
Is Frontage Holdings Corp. overvalued?
Does Frontage Holdings Corp. pay dividends?
What is Frontage Holdings Corp.’s EPS estimate?
How many shares outstanding does Frontage Holdings Corp. have?
What happened to Frontage Holdings Corp.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Frontage Holdings Corp.?
What is the TipRanks Smart Score and how is it calculated?
Frontage Holdings Corp. Stock Smart Score
Company Description
Frontage Holdings Corp.
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhongping Lin
- Employees
- 1,800
- Website
- www.frontagelab.com
- Address
- 700 Pennsylvania Drive, Exton, PA, 19341, US
Frontage Holdings Corp. (FGHQF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 3 |
| Technical Analysis | 4 | 1 | 0 |
| Moving Averages | 8 | 1 | 3 |
